Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › aspirin

aspirin

41 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of aspirin

86 trials tracked of aspirin: 43 in phase 3 or 4 and 17 with published results. The most-cited published study has 2447 citations.

86Trials tracked
43Phase 3 & 4
0Recruiting
17With published results
Phase distribution
Phase 4 26 Phase 3 17 Phase 2 28 Phase 1 4 Other / NA 11
  1. Phase 3 Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease Completed · 2,447 cited
  2. Phase 4 Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study) Completed · 1,514 cited
  3. Phase 4 Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery Completed · 242 cited
  4. Phase 3 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Completed · 175 cited
  5. Phase 4 Nephropathy In Type 2 Diabetes and Cardio-renal Events Completed · 133 cited
  6. Phase 3 Minocycline and Aspirin in the Treatment of Bipolar Depression Completed · 72 cited
Show 44 more trials
  1. Phase 3 Low Dose Aspirin for Venous Leg Ulcers Completed · 29 cited
  2. Phase 3 Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI) Completed · 25 cited
  3. Phase 4 Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor Completed · 22 cited
  4. Phase 3 Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk Completed · 21 cited
  5. Phase 4 Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus Completed · 19 cited
  6. Phase 4 PROMUS Element Plus US Post-Approval Study Completed · 16 cited
  7. Phase 3 Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes Completed · 14 cited
  8. Phase 4 Clopidogrel and Aspirin Interaction Study-2 Completed · 11 cited
  9. Phase 4 Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Completed · 10 cited
  10. Phase 4 Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis Completed · 9 cited
  11. Phase 4 Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention Completed · 8 cited
  12. Phase 4 Pharmacogenomics of Antiplatelet Response - II (PARes-II) Completed
  13. Phase 4 Pharmacogenomics of Antiplatelet Response Completed
  14. Phase 4 Pharmacogenomics of Antiplatelet Response - I Completed
  15. Phase 4 DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation Completed
  16. Phase 4 Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy Completed
  17. Phase 4 CES1 Carriers in the PAPI Study Completed
  18. Phase 4 The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin Completed
  19. Phase 4 Aspirin Dosing in Diabetic Patients Completed
  20. Phase 4 Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2) Completed
  21. Phase 4 A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers Completed
  22. Phase 4 Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome Completed
  23. Phase 4 Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study) Completed
  24. Phase 4 Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler Completed
  25. Phase 4 Aspirin Responsiveness in Women at Risk for Cardiac Events Completed
  26. Phase 4 Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty Completed
  27. Phase 4 Aspirin Dose and Atherosclerosis in Patients With Heart Disease Completed
  28. Phase 3 Omega-3 Fatty Acids Plus Low-dose Aspirin Daily Supplementation in Surgical Therapy to Treat Aggressive Periodontitis Completed
  29. Phase 3 Omega-3 Plus Low-dose Aspirin Daily Supplementation in Non-surgical Therapy to Treat Aggressive Periodontitis Completed
  30. Phase 3 Aspirin in Young Psychotic Patients Completed
  31. Phase 3 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Completed
  32. Phase 3 PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK) Completed
  33. Phase 3 A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. Completed
  34. Phase 3 Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial Completed
  35. Phase 3 The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions Completed
  36. Phase 3 The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL) Completed
  37. Phase 3 Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer Completed
  38. Phase 2 Trial of Aspirin and Arginine Restriction in Colorectal Cancer Completed
  39. Phase 2 Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma Completed
  40. Phase 2 Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer Completed
  41. Phase 2 Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes" Completed
  42. Phase 2 The Effects of DHA on Periodontitis Completed
  43. Phase 2 Targeting Platelets in Chronic HIV Infection Completed
  44. Phase 2 Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules Completed

Showing the 50 most-cited and recently-updated of 86 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
MDT-guided perioperative strategy and staged anticoagulation manage pancreatic cancer in a patient with Moyamoya disease
Oncology Guideline
MDT-guided perioperative strategy and staged anticoagulation manage pancreatic cancer in a patient with Moyamoya disease Multidisciplinary Strategy Helps Manage Moyamoya Disease and Pancreatic Cancer
This case report describes a multidisciplinary team-guided perioperative strategy for a patient with Moyamoya disease and pancreatic ductal …
A specialized surgical strategy helped a patient with both Moyamoya disease and pancreatic cancer undergo surgery without any neurological c…
Frontiers Sep 14, 2026
Low Dose Ticagrelor and Aspirin Reduce Early Neurological Deterioration in Ischemic Stroke
Neurology RCT
Low Dose Ticagrelor and Aspirin Reduce Early Neurological Deterioration in Ischemic Stroke Trial shows ticagrelor and aspirin may reduce neurological decline
A randomized trial suggests that low-dose ticagrelor combined with aspirin significantly reduces early neurological deterioration in high-ri…
A new clinical trial suggests that a specific combination of ticagrelor and aspirin may help prevent early neurological decline after a stro…
Sep 10, 2026
Clopidogrel monotherapy reduces bleeding risk to 2.1% versus 3.2% in patients with acute coronary syndromes
Diabetes & Endocrinology RCT
Clopidogrel monotherapy reduces bleeding risk to 2.1% versus 3.2% in patients with acute coronary syndromes Trial shows clopidogrel alone reduces bleeding risk after heart procedures
This prespecified subgroup analysis of a randomized controlled trial involving 7758 patients with acute coronary syndromes found that clopid…
Patients with heart conditions may face fewer bleeding risks by switching to clopidogrel alone after a period of dual therapy.
Sep 4, 2026
Ticagrelor monotherapy following primary PCI for STEMI shows reduced non-access site bleeding
Cardiology RCT
Ticagrelor monotherapy following primary PCI for STEMI shows reduced non-access site bleeding Trial shows ticagrelor monotherapy may reduce bleeding after heart attack
This pilot study compared ticagrelor monotherapy against ticagrelor plus aspirin in patients with STEMI after primary PCI. The trial reporte…
A pilot study suggests that using ticagrelor alone after a heart attack may reduce specific types of bleeding compared to a dual-drug approa…
Sep 2, 2026
Clopidogrel plus aspirin for 21 days provides favorable net clinical benefit in minor ischemic stroke
Neurology Sys. Review
Clopidogrel plus aspirin for 21 days provides favorable net clinical benefit in minor ischemic stroke Dual antiplatelet therapy shows mixed results for stroke prevention
This Bayesian network meta-analysis of 8 trials involving 50,349 adults with minor ischemic stroke or high-risk TIA found that clopidogrel p…
New data compares different blood thinner combinations to find the best way to prevent a second stroke after a minor medical emergency.
Sep 1, 2026
Dual antiplatelet therapy reduces major ischemic events in week 1 of minor stroke or TIA
Neurology Meta-analysis
Dual antiplatelet therapy reduces major ischemic events in week 1 of minor stroke or TIA Dual antiplatelet therapy reduces stroke risk in first week
This meta-analysis of 27,167 patients with minor ischemic stroke or high-risk TIA found that DAPT significantly reduced major ischemic event…
A new analysis shows dual antiplatelet therapy significantly lowers stroke risk in the first week, but carries a higher risk of bleeding.
Sep 1, 2026
Impact of Early Aspirin Withdrawal on Myocardial Infarction in Patients After PCI
Cardiology Meta-analysis
Impact of Early Aspirin Withdrawal on Myocardial Infarction in Patients After PCI Aspirin withdrawal shortly after heart procedures may increase heart attack risk
Early aspirin withdrawal within 30 days post-PCI significantly increases myocardial infarction risk, despite long-term reductions in bleedin…
Stopping aspirin within 30 days of a heart procedure may increase the risk of a heart attack in the first month.
Sep 1, 2026
Ticagrelor monotherapy after primary PCI shows 3.1% MACCE versus 2.0% in DAPT group
Cardiology RCT
Ticagrelor monotherapy after primary PCI shows 3.1% MACCE versus 2.0% in DAPT group Trial shows ticagrelor alone may reduce bleeding after heart attack
This pilot randomized controlled trial of 200 STEMI patients compared ticagrelor monotherapy to ticagrelor plus aspirin (DAPT) after primary…
A new trial looks at whether using one blood thinner instead of two can reduce bleeding risks for patients after a heart attack.
Sep 1, 2026
Aspirin associated with reduced risk of disability loss in specific elderly populations
Geriatrics & Aging RCT
Aspirin associated with reduced risk of disability loss in specific elderly populations Trial shows aspirin may lower risk of disability for some
Researchers conducted a post hoc analysis of a trial involving older adults to evaluate the impact of daily aspirin on disability-free survi…
A trial of over 1,200 seniors found that daily aspirin may lower the risk of death, disability, or dementia for specific groups.
medRxiv Aug 27, 2026
DOAC therapy reduces odds of symptomatic ischemic stroke compared to aspirin monotherapy
Neurology Meta-analysis
DOAC therapy reduces odds of symptomatic ischemic stroke compared to aspirin monotherapy Direct oral anticoagulants show lower risk of stroke than aspirin
This meta-analysis of 3666 patients evaluated DOAC therapy versus aspirin for ischemic cerebrovascular disease. The analysis found a lower o…
New data shows that direct oral anticoagulants may offer better protection against symptomatic strokes compared to taking aspirin alone.
Aug 1, 2026
Ticagrelor reduces mortality and major adverse cardiovascular events compared to clopidogrel in STEMI patients
Cardiology Meta-analysis
Ticagrelor reduces mortality and major adverse cardiovascular events compared to clopidogrel in STEMI patients Ticagrelor Shows Lower Mortality Risk Than Clopidogrel for Heart Patients
This meta-analysis of 31,729 adult STEMI patients post-PCI found that ticagrelor significantly reduced all-cause mortality (OR = 0.64) and m…
A large analysis of over 31,000 patients suggests ticagrelor may lower mortality and heart attack risks compared to clopidogrel after a hear…
NEJM Jul 26, 2026
Lower aspirin doses combined with clopidogrel may reduce ischemic events in high risk patients
Cardiology RCT
Lower aspirin doses combined with clopidogrel may reduce ischemic events in high risk patients Lower Aspirin Doses May Be Safer for Patients After Minor Strokes
Researchers analyzed data from a trial involving patients with transient ischemic attack and minor stroke receiving dual antiplatelet therap…
Doctors found that taking a lower dose of aspirin with clopidogrel may reduce the risk of serious heart and brain events.
Jul 21, 2026

All aspirin Articles